PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2397/4/11 Warner Chilcott

Hospital consultant v Warner Chilcott: Asacol leavepiece claim β€œup to 72% treatment success” (AUTH/2397/4/11)

A consultant challenged an Asacol leavepiece claiming β€œup to 72% treatment success”. The Panel found breaches, but on appeal the Appeal Board…

2011
CASE
AUTH/2389/2/11 Alcon Laboratories

AUTH/2389/2/11: Allergan v Alcon β€” Travatan β€œthornless rose” visual and lab-data tolerability claims

Alcon’s Travatan BAK-free ad used a thornless rose and animal/in vitro data implying better tolerability vs BAK formulation. PMCPA found the ad…

2018
CASE
AUTH/3088/9/18 Ipsen

AUTH/3088/9/18: Director v Ipsen (Clinical trial disclosure) – No breach

BMJ analysis suggested 3 Ipsen trials were missing EUCTR results. Panel found 2 trials had no UK nexus and 1 was cancelled…

2008
CASE
Abbott Laboratories

Abbott voluntary admission: representative worked without passing ABPI Medical Representatives Examination (Clause 16.3)

Abbott disclosed that one representative had not taken/passed the ABPI Medical Representatives Examination after exemptions ended in 2006. PMCPA ruled a breach…

2008
CASE
AstraZeneca ⭐ Case of the Week

AstraZeneca & Bristol-Myers Squibb: Onglyza advert in Health Service Journal (audience targeting) – no breach on appeal

Two public complaints said an Onglyza advertorial in Health Service Journal was inappropriate/too technical and potentially public-facing. Panel found a Clause 11.1…

2018
CASE
AUTH/3117/11/18 Seqirus

AUTH/3117/11/18: Director v Seqirus (Clinical trial disclosure) – Outwith scope of the Code

PMCPA case AUTH/3117/11/18 (Director v Seqirus) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…

2018
CASE
AUTH/3097/9/18 Teva

AUTH/3097/9/18: Director v Teva β€” Clinical trial disclosure on EUCTR (No breach after appeal)

BMJ analysis suggested Teva had unreported EUCTR trial results (72% disclosed). Panel initially found Clause 9.1 breaches for two UK-nexus trials, but…

2012
CASE
AUTH/2516/6/12 Merz Pharma UK

AUTH/2516/6/12: Allergan/PMCPA Director v Merz β€” Bocouture ad implied 1:1 interchangeability with Botox (breach of undertaking)

Merz’s Bocouture ad in Cosmetic News implied 1:1 clinical conversion/equal potency vs Botox. PMCPA ruled it breached a prior undertaking and failed…

2012
CASE
AUTH/2495/3/12 ALK-AbellΓ³

AUTH/2495/3/12: Pharmacist v ALK-AbellΓ³ (Jext vs EpiPen) – No breach

A pharmacist alleged an ALK-AbellΓ³ rep wrongly said EpiPen was discontinued, Jext administration was identical, and Jext had 24-month shelf life. Panel…

2012
CASE
AUTH/2473/1/12 Vifor Pharma ⭐ Case of the Week

AUTH/2473/1/12: Vifor Pharma – Ferinject journal ads not UK-certified (Clause 14.1 x3)

Vifor voluntarily admitted three Ferinject ads placed by global colleagues in international journals were not certified under the UK ABPI Code. PMCPA…

2011
CASE
AUTH/2448/10/11 Boehringer Ingelheim

AUTH/2448/10/11: Pharmacist complaint about Pradaxa β€˜Stroke Prevention’ leavepieces and representative conduct (No breach on appeal)

Pharmacist challenged Pradaxa β€˜Stroke Prevention’ leavepieces and a rep’s presentation as misleading on tolerability and GI bleeding. Panel found breaches, but Appeal…

2012
CASE
Novartis Pharmaceuticals UK

Journalist v Novartis: Daily Mail article alleged to promote Xolair via third-party links (No breach)

A journalist alleged a Daily Mail Online story was covert promotion of Xolair linked to Novartis contacts and a pack shot. PMCPA…

2012
CASE
AUTH/2554/11/12 Ipsen

Ipsen: ISU Belfast meeting sponsorship criticised for overall impression of luxury venue and social programme (AUTH/2554/11/12)

Ipsen UK was ruled in breach of Clause 9.1 after supporting an ISU urology meeting at a 5-star Belfast venue where the…

2013
CASE
AUTH/2601/5/13 Gedeon Richter

Gedeon Richter breached an undertaking after a meeting invitation stayed live online without prescribing information (AUTH/2601/5/13)

An ex-employee alleged a meeting invitation remained on an events website after an undertaking was signed. The Panel ruled Gedeon Richter failed…

2013
CASE
AUTH/2575/2/13 Gedeon Richter ⭐ Case of the Week

Gedeon Richter: Barcelona Esmya meeting invitationsβ€”unacceptable arrangements, lack of certification, and pre-licence promotion (AUTH/2575/2/13)

Ex-employee complaint about Esmya meeting invites for Barcelona. Panel found unacceptable meeting arrangements and lack of certification (2013), plus promotion of an…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training